Navigation Links
Anesiva Announces New Zingo Marketing and Distribution Agreement
Date:4/29/2008

most common adverse events with Zingo were redness (erythema), red dots (petechiae) and swelling (edema). In March 2008, Anesiva submitted a supplemental new drug application (sNDA) to expand the label indication for Zingo to include adults, based on a positive Phase 3 trial in nearly 700 patients.

About Anesiva and its Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA, USA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
2. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
3. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
4. Anesiva Appoints Daniel Janney to Board of Directors
5. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
6. Anesiva Announces Completion of Common Stock Offering
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
9. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
10. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... announced the appointment of Debra Zack , ... appointment of Lloyd Rowland , senior vice ... "Debra,s expertise in biologics clinical development ...
(Date:9/2/2014)... , Sept. 2, 2014  Spherix Incorporated (SPEX) -- an ... monetization of intellectual property, today announced that the United ... to the Company in the month of August that ... The issued patents are: ... U.S.RE45,081 issued August 19, 2014; and , U.S.RE45,095 ...
(Date:9/1/2014)... Albany, NewYork (PRWEB) September 01, 2014 ... Pharma, Biotech and Diagnostics report provides comprehensive understanding ... and agreements entered into by the worlds leading ... detailed understand and analysis of how and why ... flexibility of a prospective partner’s negotiated deals terms ...
(Date:8/30/2014)... 2014 The Global and China ... in-depth study on the current state of the ... , The report provides a basic overview of ... structure. Global market analysis and Chinese domestic market ... developments, trends and competitive landscape of the market. ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3
... Bioinformatics Application. Part of "Project GreenLight" Energy Efficiency Initiative. ... ... 17, 2008 -- Convey Computer Corporation today announced at SC08 ... Convey HC-1, to the University of California, San Diego as ...
... Physicists in the USA and at the London Centre for ... of electrons by more than 5,000 per cent, as reported ... a property called ,spin, and work like tiny magnets which ... The state of the spin can be used to store ...
... University of Central Florida researcher may have found a defense ... third of Europe,s population in the Middle Ages and which ... UCF Professor Henry Daniell and his team have developed a ... plague. Findings of his National Institutes of Health and USDA ...
Cached Biology Technology:Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference 2Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference 3Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference 4Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference 5UCF professor develops vaccine to protect against black plague bioterror attack 2UCF professor develops vaccine to protect against black plague bioterror attack 3
(Date:9/2/2014)... digital distribution of media will have lower carbon ... when file sizes are large. , That,s the ... Journal of Industrial Ecology that looked at ... as PlayStation3. Researchers found that Blu-ray Discs delivered ... than game files downloaded over broadband Internet. For ...
(Date:9/2/2014)... new study that could ultimately lead to many new ... Research Institute (TSRI) have adapted a chemical approach to ... that can treat a form of muscular dystrophy. , ... a disease-causing defect as a catalyst to synthesize a ... Disney.,"Because the treatment is synthesized only in diseased cells, ...
(Date:9/2/2014)... participation of the University of Granada has revealed new ... the Iberian Peninsula around the mid Holocene (around 6.000 ... from the Sahara increased. The data came from a ... in Sierra Nevada (Granada) , This study, published in ... the sedimentation of atmospheric dust from the Sahara, a ...
Breaking Biology News(10 mins):Scripps Florida scientists make diseased cells synthesize their own drug 2Scientists obtain new data on the weather 10,000 years ago from sediments of a lake in Sierra Nevada 2
... , Aug. 19, 2013 /PRNewswire-iReach/ -- Jade Holding Group, LLC dba ... and wellness centers, has just announced that Dr. Paul J. ... August. (Photo: http://photos.prnewswire.com/prnh/20130819/MN65951 ) Dr. ... in 1970 as an undergraduate at the University of Miami in ...
... microorganismshundreds to thousands of species of bacteria collectively called ... healthy existence. The gastrointestinal (GI) tractand the colon in ... of bacterial species. But how do these organisms persist ... flux due to foods and fluids moving through it? ...
... August 19, 2013 A study published today found ... accurate and precise method for quality control of next-generation sequencing ... data yield, thereby increasing efficiency and throughput while lowering cost. ... of Biotechniques . "While real-time PCR has ...
Cached Biology News:Dr. Paul J. Reilly, MD, FAAFP, is Named Strax Rejuvenation's Doctor of the Month for August 2Dr. Paul J. Reilly, MD, FAAFP, is Named Strax Rejuvenation's Doctor of the Month for August 3A home for the microbiome 2A home for the microbiome 3A home for the microbiome 4Droplet Digital™ PCR provides accurate quantification of next-generation sequencing libraries 2
... unique human proteins on a 1x3 ... a cross section of all cellular ... high-quality results. Additional control proteins and ... validity and reproducibility., ,UNIchip protein microarrays ...
... UNIchip AV-400 contains 400 unique ... nitrocellulose-coated glass slide. The proteins, all ... Ontology classification, are arrayed in quadruplicate ... and a specific chip layout guarantee ...
... The Sub-Plates are E.Coli glycerol stocks ... well contains 50 cDNA clones with approximately ... of the a master plate well, the ... 96-well PCR to identify the positive well(s). ...
... The TNT Coupled Reticulocyte Lysate ... eukaryotic in vitro translations: a single-tube, ... Systems greatly simplify the process and ... in vitro translation results. Standard rabbit ...
Biology Products: